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EDITORIAL
Utility and  limitations  of T.  gondii-speciﬁc  IgM  serum
antibodies in the diagnosis  of congenital  toxoplasmosis
in Porto Alegre,
Utilidade  e  limitac¸ões  de  anticorpos  séricos  IgM  especíﬁcos  contra  o  T.
gondii  para  o  diagnóstico  da  toxoplasmose  congênita  em  Porto  Alegre
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cCongenital  toxoplasmosis  is  associated  with  considerable
morbidity when  untreated.1--10 From  the  time  of  the  discov-
ery of  T.  gondii-speciﬁc  IgM  in  infants,11 establishing  the
diagnosis of  this  infection  has  included  the  detection  of
T. gondii-speciﬁc  IgM  antibodies  in  serum  of  the  newborn
infant. However,  whether  this  differs  and  the  robustness  of
this test  in  different  populations  and  regions  has  not  been
deﬁned. Lago,  Oliveira,  and  Bender  describe  their  experi-
ence with  the  presence  of  T.  gondii  IgM  in  sera  obtained  from
congenitally infected  infants  whose  mothers  were  tested
prenatally or  in  which  only  the  infants  themselves  were
tested in  the  newborn  period  at  a  screening  program.12
They  also  noted  the  duration  that  the  anti-T.  gondii  IgM
could still  be  detected  in  sera  from  infants  with  congenital
toxoplasmosis, in  a  carefully  performed  and  well-described
study. The  investigators  used  an  IgM  enzyme  linked  ﬂuores-
cent assay  (ELFA)  (BioMérieux  -  Marcy  l’Etoile,  France)  to
detect T.  gondii-speciﬁc  IgM  in  serum  and  a  ﬂuorometric
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and) to  detect  T.  gondii  antibody  in  serum  eluted  from  ﬁlter
aper.
These investigators  described  both  the  utility  and  limita-
ions of  testing  for  T.  gondii-speciﬁc  IgM  in  sera  of  newborn
nfants with  congenital  toxoplasmosis  in  their  region.  They
lso  highlight  the  circumstances  in  which  the  diagnosis  can
e  missed,  when  this  test  is  relied  on  exclusively.  A  careful
haracterization of  this  cohort  of  infants  is  also  presented.
here are  three  missing  sets  of  information  that  would  help
ith full  interpretation  of  their  data:  (1)  speciﬁcs  of  treat-
ent; (2)  the  reason(s)  for  the  long  time  lag  between  ﬁnding
 positive  IgM  antibody  and  initiating  treatment  for  the
roup of  infants  diagnosed  with  newborn  screening,  and  (3)
lariﬁcation  of  why  only  ultrasound  of  the  brain  was  used
ithout brain  computed  tomography  for  some  infants,  and
ow many  these  were,  since  computed  tomography  is  more
ensitive for  the  detection  of  intracerebral  calciﬁcations.
This  study12 took  place  in  Porto  Alegre,  in  Rio  Grande  do
ul, Brazil,  from  1998  to  2009,  and  involved  65  infants.  Inclu-
ion criteria  for  the  study  were:  routine  maternal  or  newborn
erologic screening;  diagnostic  conﬁrmation  with  persistent
gG anti-T.  gondii  at  age  at  12  months  or  later;  and  screening
or Toxo-IgM  in  the  newborn  period.  They  calculated  the
requency of  positive  Toxo-IgM,  and  of  cases  identiﬁed  by
ewborn screening  that  were  excluded.  They  excluded  new-
orns whose  age  when  Toxo-IgM  results  became  negative  was
ot ascertainable  and  patients  with  negative  Toxo-IgM.
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Among  the  28  patients  identiﬁed  through  maternal
creening, 23  newborns  had  positive  Toxo-IgM  (82.1%;  95%
I: 64.7-93.1%).  When  they  added  37  patients  identiﬁed  by
eonatal screening,  Toxo-IgM  was  positive  in  the  ﬁrst  month
f life  in  60  patients.  It  was  possible  to  identify  when  the
esult became  negative  in  51  of  these  infants.  In  19.6%  of
atients, these  antibodies  were  already  negative  at  30  days
f life;  and  in  54.9%,  at  90  days.  Among  the  65  patients
ncluded in  the  study,  40  (61.5%)  had  some  clinical  alter-
tion. Possible  reasons  for  the  negative  results  could  be  early
nfection and  resolution  of  production  of  IgM;  maternal  sup-
ression of  IgM  production;  and  testing  too  close  to  the  time
f acquisition  of  infection,  so  that  production  of  IgM  had
ot yet  occurred.  Differences  in  treatment  could  also  have
ltered results.
The authors  of  this  work  demonstrate  that  the  test  is
seful, but  they  also  note  that  even  when  tested  using  sero-
ogic methods  with  high  sensitivity,  up  to  one-third  of  infants
ith congenital  toxoplasmosis  may  be  negative  for  Toxo-IgM
n serum  at  birth.  Thus,  presence  of  IgM  speciﬁc  for  T.  gondii
s helpful,  but  its  absence  does  not  exclude  the  congenital
nfection. Therefore,  they  make  the  important  point  that
f there  is  a  suspicion  of  infection,  the  serologic  screening
hould continue  during  the  ﬁrst  year  of  life.
Furthermore,  in  cases  of  maternal  infection  that
ccurred very  close  to  the  time  of  delivery,  newborns  can
how positive  serology  for  toxoplasmosis  a  few  days  or  weeks
fter birth.  Thus,  retesting  is  needed  in  the  ﬁrst  month  of  life
n that  setting.  This  is  a  second  important  point  for  clinical
are of  such  infants.
The period  of  positivity  for  Toxo-IgM  was  also  not  con-
istent for  all  such  infants.  Infected  children  with  positive
oxo-IgM in  newborn  screening  may  already  be  negative  at
he time  of  conﬁrmatory  testing.  Thus,  such  testing  should
ot be  initially  regarded  as  false  positivity  for  the  screening
est. This  is  a  point  worth  emphasizing  for  the  clinical  care
f such  infants.  Without  clariﬁcation  of  how  mothers  dur-
ng gestation  and  infants  were  treated,  the  time  interval  for
gM speciﬁc  for  T.  gondii  to  remain  positive  is  difﬁcult  to
nterpret. From  the  information  in  the  article,  the  reason
or the  time  lag  to  treatment  for  those  infants  whose  con-
enital toxoplasmosis  was  detected  with  newborn  screening
s opposed  to  maternal  screening  is  not  clear.  It  is  notewor-
hy that  Desmonts  and  Couvreur  found  that  the  ﬁrst  month
f life  was  a  postnatal  time  when  it  was  possible  to  isolate
arasites from  blood.13 Thus,  it  is  noteworthy  that  the  lag  in
ime to  treat  was  on  average  this  ﬁrst  month  in  the  data  pre-
ented by  Lago  et  al.12 Nonetheless,  the  same  observations
n this  paper  allowed  for  determination  of  the  persistence
f IgM  speciﬁc  for  T.  gondii,  and  provide  evidence  that  it  is
mportant not  to  discontinue  monitoring  of  infants  with  sus-
ected  congenital  toxoplasmosis  for  synthesis  of  T.  gondii
peciﬁc IgG  when  there  is  a  negative  Toxo-IgM  result.
The  careful  description  by  Lago  et  al.  of  IgM  speciﬁc  for  T.
ondii in  congenitally  infected  children  born  in  Porto  Alegre
lso presents  how  this  infection  currently  is  manifested  and
anaged in  that  city,  where  the  incidence  of  this  infection  is
uite high.  The  high  incidence  of  retina  and/or  central  ner-
ous system  ﬁndings  in  infants  with  congenital  toxoplasmosis
n Belo  Horizonte,  Minas  Gerais,  Brazil14 is  also  found  to  be
imilar in  Porto  Alegre  in  the  present  study.  The  incidence  of
ctive retinitis  was  not  as  high  as  Vasconcelos-Santos  et  al.McLeod  R
eported  for  the  Belo  Horizonte/Fiocruz  cohort,  where  73%
f the  newborn  infants  detected  by  screening  had  active
horioretinitis. There  was  a  trend  toward  a  lower  number  of
nfants having  T.  gondii  speciﬁc  IgM  when  there  was  prenatal
creening and  treatment  (speciﬁc  treatment  not  speciﬁed)
s has  been  demonstrated  by  Couvreur  and  Desmonts,13 but
hat did  not  reach  statistical  signiﬁcance  in  the  Porto  Alegre
ohort. It  is  not  clear  whether  this  reﬂects  the  type  or  timing
f treatment,  or  something  about  the  parasite.  In  the  United
tates, where  there  are  a  variety  of  different  genetic  types
f parasites,  prenatal  diagnosis  and  treatment  appeared  to
mprove outcomes  for  all  of  them,  and  this  did  not  vary  by
arasite type.15 This  improvement  in  outcomes  is  similar  to
hat described  in  France.16--20
This  work  demonstrates  the  beneﬁt  and  utility  of  diagno-
is and  initiation  of  treatment  in  a  pre-natal  and  neonatal
creening program  in  Porto  Alegre.  The  ﬁnding  that  testing
t birth  with  the  IgM  assay  (ELFA,  BioMérieux)  speciﬁc  for
. gondii  infection  aids  in  the  diagnosis  of  congenital  toxo-
lasmosis in  Porto  Alegre  is  useful.  However,  it  is  important
lso to  note  that  the  absence  of  T.  gondii-speciﬁc  IgM  anti-
ody does  not  exclude  the  infection.  Thus,  an  important
aveat is  that  such  testing  should  not  prevent  subsequent
ntibody testing  to  make  the  diagnosis  by  later  production
f IgG  antibody,  when  this  infection  is  suspected,  as  such
egative tests  can  occur  in  a  number  of  settings  and  for  a
umber of  distinct  reasons.
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